Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Debt: 2020

  • Foghorn Therapeutics' Non-Current Debt was N/A to $19.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $19.7 million, marking a year-over-year change of. This contributed to the annual value of $19.7 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Debt of $19.7 million as of Q4 2020, which was up 123.32% from $8.8 million recorded in Q3 2020.
  • Over the past 5 years, Foghorn Therapeutics' Non-Current Debt peaked at $19.7 million during Q4 2020, and registered a low of $8.8 million during Q3 2020.
  • Over the past 1 years, Foghorn Therapeutics' median Non-Current Debt value was $14.2 million (recorded in 2020), while the average stood at $14.2 million.